vs
GRIFFON CORP（GFF）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
UNITED THERAPEUTICS Corp的季度营收约是GRIFFON CORP的1.2倍（$790.2M vs $649.1M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs 9.9%，领先36.2%），UNITED THERAPEUTICS Corp同比增速更快（7.4% vs 2.6%），UNITED THERAPEUTICS Corp自由现金流更多（$173.3M vs $99.3M），过去两年UNITED THERAPEUTICS Corp的营收复合增速更高（8.0% vs -1.8%）
格里芬公司是总部位于纽约的跨国多元化控股集团，业务覆盖多领域运营，旗下拥有Ames True Temper、ClosetMaid、Clopay建筑产品和CornellCookson四大子公司。该公司1961年起在纽交所公开上市，是标普小盘600指数、标普1500综合指数及罗素2000指数的成分股。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
GFF vs UTHR — 直观对比
营收规模更大
UTHR
是对方的1.2倍
$649.1M
营收增速更快
UTHR
高出4.7%
2.6%
净利率更高
UTHR
高出36.2%
9.9%
自由现金流更多
UTHR
多$74.0M
$99.3M
两年增速更快
UTHR
近两年复合增速
-1.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $649.1M | $790.2M |
| 净利润 | $64.4M | $364.3M |
| 毛利率 | 41.1% | 86.9% |
| 营业利润率 | 17.5% | 45.1% |
| 净利率 | 9.9% | 46.1% |
| 营收同比 | 2.6% | 7.4% |
| 净利润同比 | -9.1% | 20.9% |
| 每股收益（稀释后） | $1.41 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GFFUTHR
| Q4 25 | $649.1M | $790.2M | ||
| Q3 25 | $662.2M | $799.5M | ||
| Q2 25 | $613.6M | $798.6M | ||
| Q1 25 | $611.7M | $794.4M | ||
| Q4 24 | $632.4M | $735.9M | ||
| Q3 24 | $659.7M | $748.9M | ||
| Q2 24 | $647.8M | $714.9M | ||
| Q1 24 | $672.9M | $677.7M |
净利润GFFUTHR
| Q4 25 | $64.4M | $364.3M | ||
| Q3 25 | $43.6M | $338.7M | ||
| Q2 25 | $-120.1M | $309.5M | ||
| Q1 25 | $56.8M | $322.2M | ||
| Q4 24 | $70.9M | $301.3M | ||
| Q3 24 | $62.5M | $309.1M | ||
| Q2 24 | $41.1M | $278.1M | ||
| Q1 24 | $64.1M | $306.6M |
毛利率GFFUTHR
| Q4 25 | 41.1% | 86.9% | ||
| Q3 25 | 41.7% | 87.4% | ||
| Q2 25 | 43.2% | 89.0% | ||
| Q1 25 | 41.2% | 88.4% | ||
| Q4 24 | 41.8% | 89.7% | ||
| Q3 24 | 39.9% | 88.9% | ||
| Q2 24 | 38.5% | 89.1% | ||
| Q1 24 | 40.2% | 89.2% |
营业利润率GFFUTHR
| Q4 25 | 17.5% | 45.1% | ||
| Q3 25 | 18.0% | 48.6% | ||
| Q2 25 | -20.5% | 45.6% | ||
| Q1 25 | 16.5% | 48.2% | ||
| Q4 24 | 17.7% | 48.6% | ||
| Q3 24 | 16.9% | 45.8% | ||
| Q2 24 | 13.8% | 44.7% | ||
| Q1 24 | 16.9% | 52.6% |
净利率GFFUTHR
| Q4 25 | 9.9% | 46.1% | ||
| Q3 25 | 6.6% | 42.4% | ||
| Q2 25 | -19.6% | 38.8% | ||
| Q1 25 | 9.3% | 40.6% | ||
| Q4 24 | 11.2% | 40.9% | ||
| Q3 24 | 9.5% | 41.3% | ||
| Q2 24 | 6.3% | 38.9% | ||
| Q1 24 | 9.5% | 45.2% |
每股收益（稀释后）GFFUTHR
| Q4 25 | $1.41 | $7.66 | ||
| Q3 25 | $1.04 | $7.16 | ||
| Q2 25 | $-2.65 | $6.41 | ||
| Q1 25 | $1.21 | $6.63 | ||
| Q4 24 | $1.49 | $6.23 | ||
| Q3 24 | $1.29 | $6.39 | ||
| Q2 24 | $0.84 | $5.85 | ||
| Q1 24 | $1.28 | $6.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $95.3M | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $108.9M | $7.1B |
| 总资产 | $2.1B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GFFUTHR
| Q4 25 | $95.3M | $2.9B | ||
| Q3 25 | $99.0M | $2.8B | ||
| Q2 25 | $107.3M | $3.0B | ||
| Q1 25 | $127.8M | $3.3B | ||
| Q4 24 | $152.0M | $3.3B | ||
| Q3 24 | $114.4M | $3.3B | ||
| Q2 24 | $133.5M | $3.0B | ||
| Q1 24 | $123.0M | $2.7B |
总债务GFFUTHR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.6B | — |
股东权益GFFUTHR
| Q4 25 | $108.9M | $7.1B | ||
| Q3 25 | $74.0M | $6.6B | ||
| Q2 25 | $63.9M | $7.2B | ||
| Q1 25 | $214.7M | $6.8B | ||
| Q4 24 | $227.8M | $6.4B | ||
| Q3 24 | $224.9M | $6.1B | ||
| Q2 24 | $223.5M | $5.7B | ||
| Q1 24 | $202.2M | $5.3B |
总资产GFFUTHR
| Q4 25 | $2.1B | $7.9B | ||
| Q3 25 | $2.1B | $7.4B | ||
| Q2 25 | $2.1B | $7.9B | ||
| Q1 25 | $2.3B | $7.7B | ||
| Q4 24 | $2.3B | $7.4B | ||
| Q3 24 | $2.4B | $7.1B | ||
| Q2 24 | $2.4B | $6.7B | ||
| Q1 24 | $2.4B | $6.5B |
负债/权益比GFFUTHR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 22.71× | — | ||
| Q1 25 | 7.16× | — | ||
| Q4 24 | 6.48× | — | ||
| Q3 24 | 6.78× | — | ||
| Q2 24 | 6.74× | — | ||
| Q1 24 | 7.84× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $107.0M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | $99.3M | $173.3M |
| 自由现金流率自由现金流/营收 | 15.3% | 21.9% |
| 资本支出强度资本支出/营收 | 1.2% | 21.9% |
| 现金转化率经营现金流/净利润 | 1.66× | 0.95× |
| 过去12个月自由现金流最近4个季度 | $278.9M | $1.0B |
8季度趋势，按日历期对齐
经营现金流GFFUTHR
| Q4 25 | $107.0M | $346.2M | ||
| Q3 25 | $75.0M | $562.1M | ||
| Q2 25 | $123.1M | $191.7M | ||
| Q1 25 | $16.5M | $461.2M | ||
| Q4 24 | $142.9M | $341.2M | ||
| Q3 24 | $72.1M | $377.2M | ||
| Q2 24 | $122.1M | $232.2M | ||
| Q1 24 | $39.8M | $376.5M |
自由现金流GFFUTHR
| Q4 25 | $99.3M | $173.3M | ||
| Q3 25 | $62.4M | $351.6M | ||
| Q2 25 | $114.4M | $129.5M | ||
| Q1 25 | $2.8M | $386.3M | ||
| Q4 24 | $125.5M | $254.5M | ||
| Q3 24 | $51.6M | $300.7M | ||
| Q2 24 | $107.5M | $187.1M | ||
| Q1 24 | $20.8M | $338.3M |
自由现金流率GFFUTHR
| Q4 25 | 15.3% | 21.9% | ||
| Q3 25 | 9.4% | 44.0% | ||
| Q2 25 | 18.6% | 16.2% | ||
| Q1 25 | 0.5% | 48.6% | ||
| Q4 24 | 19.8% | 34.6% | ||
| Q3 24 | 7.8% | 40.2% | ||
| Q2 24 | 16.6% | 26.2% | ||
| Q1 24 | 3.1% | 49.9% |
资本支出强度GFFUTHR
| Q4 25 | 1.2% | 21.9% | ||
| Q3 25 | 1.9% | 26.3% | ||
| Q2 25 | 1.4% | 7.8% | ||
| Q1 25 | 2.2% | 9.4% | ||
| Q4 24 | 2.8% | 11.8% | ||
| Q3 24 | 3.1% | 10.2% | ||
| Q2 24 | 2.2% | 6.3% | ||
| Q1 24 | 2.8% | 5.6% |
现金转化率GFFUTHR
| Q4 25 | 1.66× | 0.95× | ||
| Q3 25 | 1.72× | 1.66× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | 0.29× | 1.43× | ||
| Q4 24 | 2.02× | 1.13× | ||
| Q3 24 | 1.15× | 1.22× | ||
| Q2 24 | 2.97× | 0.83× | ||
| Q1 24 | 0.62× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GFF
| Consumer And Professional Products | $241.1M | 37% |
| Residential Repairand Remodel | $202.1M | 31% |
| International Excluding North America | $97.8M | 15% |
| Retail | $47.3M | 7% |
| Residential New Construction | $32.5M | 5% |
| Other | $14.2M | 2% |
| Industrial | $14.1M | 2% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
